Toggle navigation
Home
Search
Services
Blog
Contact
About
Phase I. in Vivo and IN Vitro Pharmacology of A Chemopreventive Agent -261025120
Fox Chase Cancer Center /Inc/
Search grants from Fox Chase Cancer Center /Inc/
Share this grant:
:
:
Abstract
Funding
Institution
Related projects
Comments
Recent in Grantomics:
Your institution
vs. funders. Who wins?
Read more...
How should you pick the next fundable research topic?
Read more...
Recently viewed grants:
A model of repair: intercellular signaling and self-organization in plant regeneration
Novel Imaging Biomarkers for Treatment Evaluation in Neurodegenerative Disorders
CTCF peptides - a new therapeutic alternative to target HIV in the brain.
Prevalence of Premenstrual Dysphoric Disorder
Control of Protein and Energy Metabolism by Epinephrine
Recently added grants:
Optical analogs to MRI contrast agents for surgical guidance of brain tumor resection
Representation and utilization of sensory uncertainty in the primate visual system
The role of TLRs, Type II IFN and Type III IFN in a Murine Model of Autoinflammation
Investigating Syndecan-1 in Hepcidin Regulation and Iron Metabolism
Learning principles from the pyrenoid, a phase-separated organelle
Abstract
Funding Agency
Agency
National Institute of Health (NIH)
Institute
Division of Cancer Prevention And Control (NCI)
Type
Research and Development Contracts (N01)
Project #
N01CN025120-001
Application #
6994820
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
2004
Total Cost
Indirect Cost
Institution
Name
Fox Chase Cancer Center /Inc/
Department
Type
DUNS #
City
State
Country
Zip Code
Related projects
NIH 2006
N01 CN
Phase I Single and Multiple-Dose Safety and Pharmacokinetic and Drug -261025120
/ Fox Chase Cancer Center /Inc/
NIH 2005
N01 CN
Phase I Single and Multiple-Dose Safety and Pharmacokinetic and Drug -261025120
/ Fox Chase Cancer Center /Inc/
NIH 2004
N01 CN
Phase I. in Vivo and IN Vitro Pharmacology of A Chemopreventive Agent -261025120
/ Fox Chase Cancer Center /Inc/
Comments
Be the first to comment on this grant